The team found patients with Parkinson’s Disease had significantly shorter median duration of exposure to ≥ 1000 lux light than controls (24.7 minutes vs 50.5 minutes; P < .001). Additionally, patients with Parkinson’s disease had a greater median nighttime light intensity than controls (12.6 minutes vs 5.5 minutes; P < .001).
The multivariable analysis showed the highest quartile of light exposure to ≥ 1000 lux light during the daytime was associated with an 8% greater sleep efficiency (95% CI, 2.1 – 13.4; P = .008) and a shorter short wake after sleep onset by 36.9 minutes (95% CI, 13.4 – 60.3; P = .002) than the lowest quartile. At night, the highest quartile of mean light intensity had significantly reduced sleep efficiency by 6.8% (95% CI, 1.3 – 12.3; P = .016) and had a longer short wake after sleep onset by 24.1 minutes (95% CI, 1.8 – 46.4; P = .034), longer sleep onset latency by 0.7 minutes (95% CI, 0.3 – 1.0; P < .001), and a greater fragmentation index by -.3 log units (95% CI, 0.0 – 0.5; P = .006).
The study suggests patients with Parkinson’s disease have lower daytime light exposure with a mean light intensity of 201.1 lux (interquartile range [IQR], 101.2 – 305.7) than controls with 337.7 lux (IQR, 165.6 – 719) (P < .001). Furthermore, patients with Parkinson’s disease had higher nighttime exposure with light intensities of 2.0 (IQR, 0.5 – 7.8) than controls with 0.7 lux (IQR, 0.1 – 3.3) (P < .001)
Moreover, objective sleep measures, except for sleep onset latency, were worse in patients with Parkinson’s disease than controls (mean sleep efficiency: P < 0.001; wake after sleep onset: P < .001; fragmentation index: P < .0001) and mean total sleep time: P < .001). For patients with Parkinson’s disease, greater daylight exposure and lower nighttime light exposure were significantly linked to better objective sleep measures, even after adjusting for confounders such as daytime physical activity and disease stage.
Limitations investigators highlighted included the cross-sectional design prohibiting them from making causal inferences, wrist tremors, dyskinesia, and REM sleep behavior disorders affecting actigraphy data, the control group only having light exposure and sleep measures assessed after 2 days, and light meters being invalidated. Other limitations pointed out included not randomly selecting the control group, only including a Japanese population in the sample, not adjusting for potential confounders such as disease severity and sleep disorders, cataracts, or prior cataract surgery, and the Parkinson’s disease diagnosis not being supported by myocardial scintigraphy.
“Importantly, independent associations of daytime and nighttime light exposure with objective sleep measures were detected,” investigators wrote. “Although the present study treated light intensity, it would be important not only intensity but timing and wavelength when considering effect of light on sleep.”
References
- Obayashi K, Saeki K, Tai Y, et al. Daily light exposure profiles and the association with objective sleep quality in patients with Parkinson's disease: The PHASE study. Sleep. Published online February 8, 2024. doi:10.1093/sleep/zsae036
- Cajochen C, Münch M, Kobialka S, et al. High sensitivity of human melatonin, alertness, thermoregulation, and heart rate to short wavelength light. J Clin Endocrinol Metab. 2005;90(3):1311-1316. doi:10.1210/jc.2004-0957